0000950170-24-060300.txt : 20240515 0000950170-24-060300.hdr.sgml : 20240515 20240515143740 ACCESSION NUMBER: 0000950170-24-060300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240510 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 24949470 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 690 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 690 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 8-K 1 ssy-20240510.htm 8-K 8-K
truefalseNONE00000967930000096793us-gaap:RightsMember2024-05-102024-05-100000096793us-gaap:CommonStockMember2024-05-102024-05-1000000967932024-05-102024-05-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10,2024

SunLink Health Systems Inc.

(Exact name of Registrant as Specified in Its Charter)

Georgia

001-12607

31-0621189

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

900 Circle 75 Parkway

Suite 690

Atlanta, Georgia

30339

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 770 933-7000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Shares without par value Preferred

Share Purchase Rights

SSY

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


 

 


Item 8.01 Other Events.

 

On May 10, 2024 the Board of Directors of SunLink Health Systems, Inc. amended its By-laws to add a new section 2.15 thereto relating to shareholder proposals and nominations providing as follows:

 


Section 2.15 Shareholder Proposals and Director Nominations.

 

(a)
No proposal for a shareholder vote (other than director nominations which are described in Section 2.15(b)) shall be submitted by a shareholder (a “Shareholder Proposal”) to the Corporation’s shareholders unless the shareholder submitting such proposal (the “Proponent”) shall have filed a written notice setting forth with particularity:
(i)
the name and business address of the Proponent (including each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made) and all natural persons, corporations, partnerships, trusts or any other type of legal entity or recognized ownership vehicle (collectively, “Persons”) acting in concert with the Proponent (or such beneficial owner);
(ii)
the name and address of the Proponent (including each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made) and the other Persons identified in clause (i), as they appear on the Corporation’s books (if they so appear);
(iii)
the class and number of shares of the Corporation that are owned beneficially and of record by the Proponent (including each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made) and the other Persons identified in clause (i);
(iv)
a description of the Shareholder Proposal containing all material information relating thereto, including (A) the text of the Shareholder Proposal (including the text of any resolutions proposed for consideration and, in the event that such Shareholder Proposal includes a proposal to amend these Bylaws, the language of the proposed amendment), (B) the reasons for submission of such Shareholder Proposal at the meeting and (C) any material interest in such Shareholder Proposal of each Proponent (and each beneficial owner, if any, on whose behalf the proposal is being made) and the other Persons identified in clause (i);
(v)
a description of any agreement, arrangement or understanding with respect to the Shareholder Proposal between or among the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing;
(vi)
a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of such written notice by, or on behalf of, the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being made, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, the Proponent or such beneficial owner, with respect to securities of the Corporation;

(vii)
a representation that the Proponent is a holder of record of the capital stock of the Corporation entitled to vote at such meeting and will so remain at the time of such meeting, and intends to appear in person or by proxy at the meeting to propose such business;
(viii)
a representation whether such Proponent or any beneficial owner on whose behalf the Shareholder Proposal is being made intends or is part of a group which intends (A) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve or adopt the Shareholder Proposal or (B) otherwise to solicit proxies from shareholders in support of such Shareholder Proposal;
(ix)
any other information relating to such shareholder and such beneficial owner, if any, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the proposal pursuant to and in accordance with Section 14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder; and
(x)
such other information as the Board of Directors reasonably determines is necessary or appropriate to enable the Board of Directors and shareholders of the Corporation to consider the Shareholder Proposal.

Without limiting the foregoing, the information required by clauses (iii), (v), and (vi) of this Section 2.15(a) shall be updated by the Proponent and each beneficial owner, if any, on whose behalf the Shareholder Proposal is being submitted not later than ten (10) days after the record date for the meeting to disclose such information as of the record date. The presiding officer at any shareholders’ meeting may determine that any Shareholder Proposal was not made in accordance with the procedures prescribed in these Bylaws or is otherwise not in accordance with law, and if it is so determined, such officer shall so declare at the meeting and the Shareholder Proposal shall be disregarded. Notwithstanding anything in these Bylaws to the contrary, no provision of these Bylaws shall affect any rights of shareholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 of the Exchange Act.

(b)
Only persons who are selected and recommended by the Board of Directors or the committee of the Board of Directors designated to make nominations, or who are nominated by shareholders in accordance with the procedures set forth in this Section 2.15(b), shall be eligible for election, or qualified to serve, as directors. Nominations of individuals for election to the Board of Directors at any annual meeting or any special meeting of shareholders at which directors are to be elected may be made by any shareholder of the Corporation entitled to vote for the election of directors at that meeting by compliance with the procedures set forth in this Section 2.15(b). Nominations by shareholders shall be made by written notice (a “Nomination Notice”), which shall set forth:
(i)
as to each individual nominated: (A) the name, date of birth, business address and residence address of such individual, (B) the educational background and the business experience during the past five (5) years of such nominee, including his or her principal occupations and employment during such period, the name and principal business of any corporation or other organization in which such occupations and employment were carried on, and such other information as to the nature of his or her responsibilities and level of professional competence as may be sufficient to permit assessment of his or her prior business experience, (C) whether the nominee is or has ever been at any time a director, officer or owner of five percent (5%) or more of any class of capital stock, partnership interests or other equity interest of any corporation, partnership or other entity, (D) any directorships held by such nominee in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the

Exchange Act or any company registered as an investment company under the Investment Company Act of 1940, as amended, (E) whether such nominee has ever been convicted in a criminal proceeding or has ever been subject to a judgment, order, finding or decree of any federal, state or other governmental entity, concerning any violation of federal, state or other law, or any proceeding in bankruptcy, which conviction, order, finding, decree or proceeding may be material to an evaluation of the ability or integrity of the nominee, (F) whether such nominee is subject to any disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act of 1933, as amended, and, if so, a description in writing of all matters triggering such disqualification; (G) any other information relating to such nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Exchange Act, (H) a written statement from the shareholder making the recommendation stating why such recommended candidate meets the criteria and would be able to fulfill the duties of a director, and (I) a written representation and agreement (in the form provided by the Secretary upon written request) that (1) such nominee is not and will not become a party to (i) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (ii) any Voting Commitment that could limit or interfere with such nominee’s ability to comply, if elected as a director of the Corporation, with such nominee’s fiduciary duties under applicable law, (2) such nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, and (3) such nominee, in such nominee’s individual capacity and on behalf of any person or entity on whose behalf the nomination is being made, would be in compliance, if elected as a director of the Corporation, and will comply, with all applicable corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation, and
(ii)
as to the Person submitting the Nomination Notice, each beneficial owner, if any, on whose behalf the nomination is made and any Person acting in concert with such Persons: (A) the name and business address of such Person, (B) the name and address of each such Person as they appear on the Corporation’s books (if they so appear), (C) the class and number of shares of the Corporation that are owned beneficially and of record by each such Person, (D) a description of any agreement, arrangement or understanding with respect to the nomination between or among such Persons, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing, (E) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of such written notice by, or on behalf of, each such Person, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, each such Person, with respect to securities of the Corporation, (F) a representation that the Person submitting the Nomination Notice is a holder of record of stock of the Corporation entitled to vote at such meeting and will so remain at the time of such meeting, and intends to appear in person or by proxy at the meeting to make such nomination, (G) a representation whether any such Person intends or is part of a group which intends (1) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding

capital stock required to elect each nominee or (2) otherwise to solicit proxies from shareholders in support of such nomination, and (H) any other information relating to such shareholder and such beneficial owner, if any, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the election of directors in an election contest pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder. A written consent to being named in a proxy statement as a nominee, and to serve as a director if elected, signed by each nominee, shall be filed with any Nomination Notice. Without limiting the foregoing, the information required by clauses (ii)(C), (D), (E) and (F) of this Section 2.15(b) shall be updated by the Person delivering such Nomination Notice and each beneficial owner, if any, on whose behalf the Nomination Notice is being submitted not later than ten (10) days after the record date for the meeting to disclose such information as of the record date. The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility or qualification of such proposed nominee to serve as a director of the Corporation. If the presiding officer at any shareholders’ meeting determines that a nomination was not made in accordance with the procedures prescribed by these Bylaws or any nominee is otherwise not eligible or qualified to serve as a director, such officer shall so declare to the meeting and the defective nomination shall be disregarded.

Nomination Notices and Shareholder Proposals in connection with an annual meeting shall be delivered to the Secretary of the Corporation at the principal executive office of the Corporation not less than ninety (90) nor more than one-hundred twenty (120) calendar days before the first anniversary of the date of the Corporation’s notice of annual meeting sent to shareholders in connection with the previous year’s annual meeting; provided that if no annual meeting was held in the previous year, or the date of the annual meeting has been established to be more than thirty (30) calendar days earlier than, or sixty (60) calendar days after, the anniversary of the previous year’s annual meeting, notice by a shareholder, to be timely, must be so received not later than (i) the ninetieth (90th) day prior to the annual meeting or (ii) if later, the close of business on the tenth (10th) day following the day on which public announcement is first made of the date of the annual meeting. Nomination Notices in connection with a special meeting at which directors are to be elected shall be delivered to the Secretary of the Corporation at the principal executive office of the Corporation not later than the close of business on (i) the ninetieth (90th) day prior to such special meeting or (ii) if later, the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the fact that directors are to be elected at such meeting. Shareholder Proposals in connection with a special meeting called by the Proponent in accordance with Section 2.2 shall be included in the written requests delivered pursuant to Section 2.2. In no event shall the public announcement of an adjournment or postponement of an annual or special meeting commence a new time period (or extend any time period)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUNLINK HEALTH SYSTEMS, INC.

Date:

May 15, 2024

/s/ Mark J. Stockslager

Mark J. Stockslager

Chief Financial Officer


EX-101.SCH 2 ssy-20240510.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Right [Member] Right [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document And Entity Information Line Items Document And Entity Information [Line Items] Document And Entity Information [Line Items] No Trading Symbol Flag No Trading Symbol Flag Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Class of Stock [Domain] Class of Stock [Domain] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Class of Stock [Axis] Class of Stock [Axis] Document Period End Date Document Period End Date Document And Entity Information Table Document And Entity Information [Table] Document And Entity Information [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Common Stock [Member] Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 10, 2024
Document And Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 10, 2024
Entity Registrant Name SunLink Health Systems Inc.
Entity Incorporation, State or Country Code GA
Entity File Number 001-12607
Entity Tax Identification Number 31-0621189
Entity Address, Address Line One 900 Circle 75 Parkway
Entity Address, Address Line Two Suite 690
Entity Address, City or Town Atlanta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30339
City Area Code 770
Local Phone Number 933-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000096793
Common Stock [Member]  
Document And Entity Information [Line Items]  
Title of 12(b) Security Common Shares without par value
Trading Symbol SSY
Security Exchange Name NYSEAMER
Right [Member]  
Document And Entity Information [Line Items]  
Title of 12(b) Security Preferred Share Purchase Rights
Security Exchange Name NONE
No Trading Symbol Flag true
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - ssy-20240510.htm 8 ssy-20240510.htm ssy-20240510.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ssy-20240510.htm": { "nsprefix": "ssy", "nsuri": "http://www.sunlinkhealth.com/20240510", "dts": { "inline": { "local": [ "ssy-20240510.htm" ] }, "schema": { "local": [ "ssy-20240510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_3cc9b65a-8adb-4d6f-82b8-aee82f389d06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ssy-20240510.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3cc9b65a-8adb-4d6f-82b8-aee82f389d06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ssy-20240510.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ssy_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sunlinkhealth.com/20240510", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Document And Entity Information Line Items", "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "ssy_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sunlinkhealth.com/20240510", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Document And Entity Information Table", "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "terseLabel": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_RightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightsMember", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Right [Member]", "terseLabel": "Right [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.sunlinkhealth.com/20240510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-060300-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-060300-xbrl.zip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end XML 15 ssy-20240510_htm.xml IDEA: XBRL DOCUMENT 0000096793 us-gaap:RightsMember 2024-05-10 2024-05-10 0000096793 us-gaap:CommonStockMember 2024-05-10 2024-05-10 0000096793 2024-05-10 2024-05-10 true false NONE 0000096793 8-K 2024-05-10 SunLink Health Systems Inc. GA 001-12607 31-0621189 900 Circle 75 Parkway Suite 690 Atlanta GA 30339 770 933-7000 false false false false Common Shares without par value Preferred Share Purchase Rights SSY NYSEAMER false